Study Status: Accepting Patients
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Analysis of stem cell products immunological parameters and recipient outcome in autologous and allogeneic peripheral blood stem cell transplantation
This protocol is for the use of CliniMACS CD34 Reagent System in a single patient with relapsed AML. Patient received salvage chemo and planned stem cell boost for cytopenias. Since donor is a haplo, plan is to give CD34 selected cells with some t cell add back.
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma